Skip to main content


Springer Nature is making Coronavirus research free. View research | View latest news | Sign up for updates

Fig. 7 | Journal of Experimental & Clinical Cancer Research

Fig. 7

From: Low dose of lenalidmide and PI3K/mTOR inhibitor trigger synergistic cytoxicity in activated B cell-like subtype of diffuse large B cell lymphoma

Fig. 7

NVP-Bez235 plus lenalidomide dramatically inhibited tumor growth and prolonged the survival in a DLBCL xenograft mouse model (OCI-Ly10). a Mice in each cohort were treated with lenalidomide (10 mg/kg) every other day and NVP-Bez235 (20 mg/kg/day) alone or in combination. Tumor volumes were measured every other day for 28 days. At the end of observation, tumor growth was significantly delayed by combination treatment compared with control group (***p = 0.0003) and NVP-Bez235 treatment group (**p = 0.006). b Overall survival was prolonged by NVP-Bez235 and lenalidomide combination therapy compared with the control group and single agent group (p < 0.0001). c IHC to identify expression of Ki67, p- NF-κB of tumor specimen Tunnel assay was performed to examine the apoptosis in tissues. d, e, f Bar graph illustrate the proportion of positive cells showed in panel C. *p < 0.05, **p <0.01, *** p < 0.005 compared with the control group

Back to article page